A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy
Sponsor: Systimmune Inc.
Phase: 3
Disease: Metastatic urothelial carcinoma
EU trial number: 2026-527617-29-00
Population: Adults with HER2-expressing metastatic urothelial carcinoma (IHC 1+, 2+, or 3+) progressing during or after anti-PD-1/PD-L1-based treatment. The primary efficacy population is HER2-positive by IHC 2+ or 3+; the intention-to-treat population includes HER2 IHC 1+ to 3+.
Register Investigator Interest
Interested in offering this trial to suitable patients?